Sort   by:  
 Page size 
UnknownIn-vivo studies on Transitmycin, a potent Mycobacterium tuberculosis inhibitor.
This study involves the in-vitro and in-vivo anti-TB potency and in-vivo safety of Transitmycin (TR) (PubChem CID:90659753)- identified to be a novel secondary metabolite derived from Streptomyces sp (R2). TR was tested in-vitro against drug resistant TB clinical isolates (n = 49). 94% of DR-TB stra...
S-EPMC9983862 | biostudies-literature
UnknownGlobal, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12338332 | biostudies-literature
UnknownBurden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535840 | biostudies-literature
UnknownGlobal burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535838 | biostudies-literature
Sort   by:  
 Page size